login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
BROOKLINE CAPITAL ACQUISITIO (BCAC) Stock News
USA
- NASDAQ:BCAC -
US11374E1047
-
Common Stock
22.71
USD
+12.63 (+125.3%)
Last: 7/29/2022, 8:00:01 PM
16.11
USD
-6.6 (-29.06%)
After Hours:
7/29/2022, 8:00:01 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
BCAC Latest News, Press Relases and Analysis
All
Press Releases
3 years ago - By: Benzinga
- Mentions:
GHM
AVYA
TAST
THMO
...
This Communication Services Stock Jumped 149%; Here Are 90 Biggest Movers From Friday
3 years ago - By: Benzinga
- Mentions:
YRD
DSAC
CBAN
VTGN
...
Stocks That Hit 52-Week Lows On Friday
7 years ago - By: Xynomic Pharmaceuticals, Inc.
Xynomic Pharmaceuticals, Inc. Will Present at ASCO 2019 Annual Meeting, Will Sponsor an EU Investigator Meeting for Potentially Pivotal Kidney Cancer Trial, and Appoints Interim Chief Accounting Officer
7 years ago - By: Xynomic Pharmaceuticals, Inc.
Xynomic Pharma Achieves Important Regulatory Milestones in China and EU in Potentially Pivotal Kidney Cancer and Lymphoma Trials
7 years ago - By: TalkMarkets
- Mentions:
ASLN
Week In Review: Nanjing's NJCTTQ Agrees To $4 Billion Package For Abpro Bi-Specific Immunotherapies
7 years ago - By: Xynomic Pharmaceuticals, Inc.
Xynomic Pharma Doses First South Korean Patient in Phase 3 Renal Cell Carcinoma Trial and Hires Senior Executive Dr. Sophia Paspal to Head Regulatory Affairs and Quality Assurance
Please enable JavaScript to continue using this application.